236 related articles for article (PubMed ID: 18545995)
1. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy.
Carretero R; Romero JM; Ruiz-Cabello F; Maleno I; Rodriguez F; Camacho FM; Real LM; Garrido F; Cabrera T
Immunogenetics; 2008 Aug; 60(8):439-47. PubMed ID: 18545995
[TBL] [Abstract][Full Text] [Related]
2. HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination.
Cabrera T; Lara E; Romero JM; Maleno I; Real LM; Ruiz-Cabello F; Valero P; Camacho FM; Garrido F
Cancer Immunol Immunother; 2007 May; 56(5):709-17. PubMed ID: 16960691
[TBL] [Abstract][Full Text] [Related]
3. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations.
Aptsiauri N; Carretero R; Garcia-Lora A; Real LM; Cabrera T; Garrido F
Cancer Immunol Immunother; 2008 Nov; 57(11):1727-33. PubMed ID: 18491093
[TBL] [Abstract][Full Text] [Related]
4. Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy.
Méndez R; Ruiz-Cabello F; Rodríguez T; Del Campo A; Paschen A; Schadendorf D; Garrido F
Cancer Immunol Immunother; 2007 Jan; 56(1):88-94. PubMed ID: 16622680
[TBL] [Abstract][Full Text] [Related]
5. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.
del Campo AB; Kyte JA; Carretero J; Zinchencko S; Méndez R; González-Aseguinolaza G; Ruiz-Cabello F; Aamdal S; Gaudernack G; Garrido F; Aptsiauri N
Int J Cancer; 2014 Jan; 134(1):102-13. PubMed ID: 23784959
[TBL] [Abstract][Full Text] [Related]
6. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
7. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes.
Carretero R; Wang E; Rodriguez AI; Reinboth J; Ascierto ML; Engle AM; Liu H; Camacho FM; Marincola FM; Garrido F; Cabrera T
Int J Cancer; 2012 Jul; 131(2):387-95. PubMed ID: 21964766
[TBL] [Abstract][Full Text] [Related]
8. Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells.
Carretero R; Cabrera T; Gil H; Saenz-Lopez P; Maleno I; Aptsiauri N; Cozar JM; Garrido F
Int J Cancer; 2011 Aug; 129(4):839-46. PubMed ID: 20957629
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer.
Hanagiri T; Shigematsu Y; Shinohara S; Takenaka M; Oka S; Chikaishi Y; Nagata Y; Baba T; Uramoto H; So T; Yamada S
Anticancer Res; 2013 May; 33(5):2123-8. PubMed ID: 23645764
[TBL] [Abstract][Full Text] [Related]
10. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
Restifo NP; Marincola FM; Kawakami Y; Taubenberger J; Yannelli JR; Rosenberg SA
J Natl Cancer Inst; 1996 Jan; 88(2):100-8. PubMed ID: 8537970
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of melanoma-associated antigens and molecules involved in antigen processing and presentation in three cell lines established from a single patient.
Kovalcsik E; John J; Turner M; Birchall L; Sage D; Whittle R; Dalgleish A; Pandha H
Melanoma Res; 2004 Dec; 14(6):463-71. PubMed ID: 15577316
[TBL] [Abstract][Full Text] [Related]
12. Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma.
Mitchell MS; Jakowatz J; Harel W; Dean G; Stevenson L; Boswell WD; Groshen S
J Clin Oncol; 1994 Feb; 12(2):402-11. PubMed ID: 8113848
[TBL] [Abstract][Full Text] [Related]
13. HLA-G in melanoma: A new strategy to escape from immunosurveillance?
Ugurel S; Reinhold U; Tilgen W
Onkologie; 2002 Apr; 25(2):129-34. PubMed ID: 12006763
[TBL] [Abstract][Full Text] [Related]
14. Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.
Tjin EP; Krebbers G; Meijlink KJ; van de Kasteele W; Rosenberg EH; Sanders J; Nederlof PM; van de Wiel BA; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Cancer Immunol Res; 2014 Jun; 2(6):538-46. PubMed ID: 24894091
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
Sosman JA; Unger JM; Liu PY; Flaherty LE; Park MS; Kempf RA; Thompson JA; Terasaki PI; Sondak VK;
J Clin Oncol; 2002 Apr; 20(8):2067-75. PubMed ID: 11956267
[TBL] [Abstract][Full Text] [Related]
16. Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178.
Bettinotti MP; Panelli MC; Ruppe E; Mocellin S; Phan GQ; White DE; Marincola FM
Int J Cancer; 2003 Jun; 105(2):210-6. PubMed ID: 12673681
[TBL] [Abstract][Full Text] [Related]
17. Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy.
Mendez R; Serrano A; Jäger E; Maleno I; Ruiz-Cabello F; Knuth A; Garrido F
Tissue Antigens; 2001 Jun; 57(6):508-19. PubMed ID: 11556981
[TBL] [Abstract][Full Text] [Related]
18. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
19. Role of altered expression of HLA class I molecules in cancer progression.
Aptsiauri N; Cabrera T; Mendez R; Garcia-Lora A; Ruiz-Cabello F; Garrido F
Adv Exp Med Biol; 2007; 601():123-31. PubMed ID: 17712999
[TBL] [Abstract][Full Text] [Related]
20. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy.
Garrido F; Cabrera T; Aptsiauri N
Int J Cancer; 2010 Jul; 127(2):249-56. PubMed ID: 20178101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]